On
February 26, 2009, the FDA required the manufacturers
of metoclopramide-containing drugs such as Reglan to include a black-boxed
warning (the strongest warning available) to their drug labels about the
risk of the long-term or high-dose use. Chronic use of metoclopramide has
been linked to tardive
dyskinesia, which may include involuntary and repetitive
movements of the body, even after the drugs are no longer taken. Manufacturers
will be required to include a medication guide with their products that discusses
this risk.
According to the FDA, "Tardive dyskinesia is characterized by involuntary,
repetitive movements of the extremities, or lip smacking, grimacing, tongue
protrusion, rapid eye movements or blinking, puckering and pursing of the
lips, or impaired movement of the fingers. These symptoms are rarely reversible
and there is no known treatment. However, in some patients, symptoms may
lessen or resolve after metoclopramide treatment is stopped."
Reglan (generic name metoclopramide) is designed to be used only on a short-term
basis to treat heartburn caused by gastroesophageal
reflux, and prescribed to
patients for whom other treatments have not worked. It is also used to treat
slow gastric emptying in diabetics, a condition called diabetic gastroparesis
which causes nausea, vomiting, heartburn and loss of appetite. Additionally,
it may be used for treatment of other gastrointestinal conditions. Metoclopramide
works by speeding up the movement of the stomach muscles, increasing the rate
at which the stomach empties into the intestines. It is recommended that treatment
not exceed three months.
Metoclopramide is available in tablets, syrups and injections. Names of metoclopramide-containing
products include Reglan Tablets, Reglan Oral Disintegrating Tablets, Metoclopramide
Oral Solution, and Reglan Injection, and over two million Americans use these
products.
In addition to developing tardive dyskinesia, side effects of Reglan may include
the following:
• tremors, or restless muscle movements in your eyes, tongue, jaw, or neck;
• mask-like appearance of the face;
• fever, stiff muscles, confusion, sweating, fast or uneven heartbeats, rapid
breathing;
• depressed mood, thoughts of suicide or hurting yourself;
• hallucinations, anxiety, agitation, jittery feeling, trouble staying still;
• swelling, fluid retention;
• jaundice
• seizure (convulsions).
Less serious Reglan side effects may include:
• feeling restless, drowsy, tired, or dizzy;
• headache, sleep problems (insomnia);
• nausea, diarrhea;
• breast tenderness or swelling;
• changes in menstrual periods; or
• urinating more than usual.
"The FDA wants patients and health care professionals to know about this risk
so they can make informed decisions about treatment," said Janet Woodcock, M.D.,
director of the FDA's
Center for Drug Evaluation and Research. "The chronic use
of metoclopramide therapy should be avoided in all but rare cases where the benefit
is believed to outweigh the risk." Patients who have the highest risk include
the elderly, especially older women, who have been taking Reglan over a long
period of time.
If you or someone you know has experienced serious side effects or has tardive
dyskinesia as a result of taking Reglan, please fill out our questionnaire on
the right of this page for a free consultation.
Dangerous Drugs
News Articles
Pfizer Starts Media Ad Blitz to Address Smoking Drug Concerns
May 28 (Bloomberg) – Pfizer Inc.
(read more..)
North Carolina Case Claims Financial Calamity From Bayer Drug
5/2/08 - Triangle Business Journal
(read more..)
Panel May Issue Subpoenas Related to FDA Approval
on Antibiotic Drug Ketek
1/28/08 - FDA
(read more..)
Second Safety Warning on Fentanyl Skin Patch
12/21/07 - FDA
(read more..)
F.D.A. Investigates Quit-Smoking Drug
11/20/07 - Associated Press
(read
more..)
Merck to Pay $4.85 Billion To Settle Most Vioxx Cases
11/09/07 - AngelReyesBlog.com
(read
more..)
Cephalon Drug Is Tied to Several Deaths
9/14/07 - The Wall Street Journal
(read
more..)
$5.5 Million Award in First Federal Fentanyl (Duragesic) Pain Patch Trial
6/19/07 - Press Release
(read
more...)